Company Overview
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Why Investors Should Care
Trades at a P/E of 0.3, below the sector median of 24.8.
Carries low leverage with a debt-to-equity ratio of 0.22.
Recent Developments
- Dec 2025 Revenue of $9.44M (-13.4% YoY); net profit $-7.58M.
- Trailing 12 Months Year-on-year growth — revenue -13.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.59% |
| 1 Year: | -13.43% |
Stock Price Performance
| 1 Year: | -96.31% |
| 6 Months: | -93.83% |
| 3 Months: | -86.49% |
| 1 Month: | -68.41% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)20.58 · Oversold
P/E of 0.35 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 96.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 21 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CRIS Curis, Inc. PHARMA | 1.27 | 0.35 | $3.08M | 0.00% | -96.99% | - | 0.59% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 2.13M | 2.06M | 2.44M | 3.26M | 2.47M | 2.36M | 2.85M | 2.75M | 1.77M | 2.09M | 2.86M | 3.29M | 2.71M | 2.36M | 2.74M | 3.02M | 2.19M | 2.29M | 3.04M | 2.06M | 2.39M | 2.83M | 2.30M | 2.20M | 2.83M | 2.09M | 2.55M | 2.93M | 2.38M | 2.75M | 3.18M | 1.14M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.00K | 16.00K | 15.00K | 0 | 0 |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.37M | 2.73M | 3.16M | 1.14M | 0 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.52M | 10.98M | 10.09M | 8.71M | 11.52M |
| Operating Income | -7.37M | -4.84M | -13.25M | -8.81M | -10.68M | -27.79M | -10.76M | -15.05M | -13.11M | -14.47M | -7.13M | -9.91M | -7.86M | -6.42M | -5.15M | -5.56M | -6.14M | -5.32M | -7.33M | -8.48M | -5.43M | -4.71M | -6.28M | -8.80M | -10.65M | -10.05M | -15.13M | -15.06M | -12.61M | -11.63M | -12.14M | -12.37M | -12.47M | -12.51M | -10.57M | -10.16M | -8.25M | -6.92M | -7.57M | -11.52M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.10M | -8.21M | -6.89M | 19.97M | -11.51M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.62M | -8.59M | -7.73M | 19.36M | -24.20M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -8.13M | -5.54M | -13.46M | -9.44M | -11.29M | -28.34M | -11.34M | -15.74M | -14.09M | -15.46M | -8.03M | -10.75M | -8.66M | -7.22M | -5.94M | -9.88M | -7.21M | -6.44M | -8.61M | -9.71M | -6.71M | -5.97M | -7.52M | -9.93M | -10.84M | -11.05M | -16.11M | -15.94M | -13.29M | -11.56M | -11.96M | -12.18M | -11.88M | -11.80M | -10.09M | -10.62M | -8.59M | -7.73M | 19.36M | -24.20M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.28 | -0.17 | -0.11 | - | -0.11 | -0.12 | -0.12 | -0.18 | -0.17 | -2.83 | -2.39 | -2.47 | -2.13 | -2.05 | -2.03 | -1.70 | -25.00 | -13.60 | -9.80 | 24.60 | -25.00 |
| R&D Expense | 2.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.59M | 16.00M | 14.76M | 16.97M | 15.00M | 9.84M | 7.88M | 7.53M | 9.90M | 10.43M | 10.00M | 10.84M | 10.65M | 10.16M | 10.02M | 10.91M | 9.44M |
| Operating Income | -10.04M | -5.64M | -7.20M | -18.62M | -9.42M | -15.86M | -56.48M | -58.04M | -49.76M | -29.33M | -24.36M | -24.90M | -42.06M | -53.02M | -48.33M | -44.54M | -5.71M |
| Net Income | -9.82M | -4.44M | -9.86M | -16.42M | -12.32M | -18.73M | -58.98M | -60.41M | -53.32M | -32.58M | -32.14M | -29.91M | -45.44M | -56.67M | -47.41M | -43.39M | -7.58M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.97 | -0.61 | 0.50 | -12.14 | -8.96 | -6.88 | -0.58 |
| R&D Expense | 9.93M | 11.37M | 13.69M | 15.49M | 12.93M | 13.66M | - | 18.00M | - | - | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Sep 2010 | Dec 2010 | Sep 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Apr 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 50.65M | - | 48.18M | 69.77M | 80.59M | 62.61M | 94.97M | 57.75M | 73.80M | 37.37M | 35.11M | - | 204.36M | 162.30M | 108.85M | 77.28M | 41.27M | 19.97M |
| Total Equity | 37.22M | 33.05M | - | 45.52M | - | 39.88M | 34.27M | 45.17M | 29.78M | 64.51M | 29.45M | 23.99M | -4.50M | -33.91M | - | 130.67M | 90.71M | 46.55M | 19.67M | -6.00M | 5.46M |
| Cash & Equivalents | 10.16M | 7.28M | 7.83M | 7.83M | 15.12M | 15.12M | 12.75M | 9.59M | 7.75M | 33.09M | 26.04M | 38.29M | 23.64M | 15.43M | - | 129.61M | 40.01M | 19.66M | 26.68M | 20.00M | 5.06M |
| Long Term Debt | - | - | - | - | - | - | 29.84M | 27.95M | 22.59M | 19.56M | 14.92M | 35.67M | 28.60M | 0 | 900.00K | - | - | - | - | - | - |
| Total Liabilities | - | - | - | 5.13M | - | 8.30M | 35.50M | 35.42M | 32.83M | 30.45M | 28.49M | 49.80M | 41.86M | 69.02M | - | 73.69M | 71.59M | 62.30M | 57.61M | 47.26M | 14.50M |
| Current Liabilities | - | - | - | 3.48M | - | 3.79M | 3.98M | 6.56M | 10.07M | 10.76M | 13.55M | 14.10M | 13.25M | 6.54M | - | 10.08M | 13.44M | 10.01M | 22.02M | 19.03M | 14.08M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.59M | -1.63M | -4.56M | -15.19M | -9.54M | -16.81M | -29.89M | -35.81M | -48.35M | -30.07M | -26.20M | -25.74M | -37.62M | -54.34M | -38.43M | -39.56M | -27.20M |
| Investing Cash Flow | 818.34K | -14.89M | 9.78M | -23.00M | -13.62M | 16.27M | -6.43M | 30.12M | -3.63M | 21.37M | -4.46M | -49.05M | -47.90M | 33.02M | 37.79M | 29.44M | 2.50M |
| Financing Cash Flow | 3.89M | 17.07M | 2.08M | 35.82M | 20.00M | -1.30M | 61.66M | -1.37M | 64.23M | -5.96M | 23.27M | 188.81M | -4.17M | 867.00K | 7.58M | 3.44M | 9.77M |
| Capital Expenditure | -19.54K | -274.84K | -260.40K | -104.97K | -153.01K | -92.00K | -48.00K | -329.00K | -188.00K | -85.00K | -41.00K | -677.00K | -0 | -416.00K | -0 | - | - |
| Free Cash Flow | -7.61M | -1.90M | -4.82M | -15.30M | -9.69M | -16.91M | -29.94M | -36.14M | -48.54M | -30.15M | -26.25M | -26.42M | -37.62M | -54.75M | -38.43M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -116.9% | -35.2% | -48.8% | -109.7% | -62.8% | -161.2% | -716.9% | -771.1% | -502.7% | -281.3% | -243.5% | -229.8% | -395.0% | -521.7% | -482.2% | -408.3% | -60.5% |
| Net Margin % | -114.4% | -27.7% | -66.8% | -96.7% | -82.1% | -190.3% | -748.7% | -802.6% | -538.7% | -312.4% | -321.3% | -276.0% | -426.7% | -557.7% | -473.0% | -397.8% | -80.3% |
| ROE % | -29.7% | -9.7% | -24.7% | -47.9% | -27.3% | -62.9% | -91.4% | -205.1% | -222.2% | 724.5% | 94.8% | -22.9% | -50.1% | -121.7% | -241.0% | 723.4% | -138.8% |
| ROCE % | - | -12.0% | -16.2% | -28.3% | -12.7% | -30.2% | -67.1% | -131.3% | -83.4% | -121.6% | -85.3% | -12.8% | -28.3% | -53.6% | -87.5% | -200.3% | -97.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bleichroeder LP | 9.10% | 190.12K | $190.12K |
| 2 | Stonepine Capital Management, LLC | 7.92% | 165.61K | $165.61K |
| 3 | Nantahala Capital Management, LLC | 4.73% | 98.94K | $98.94K |
| 4 | Cable Car Capital, LP | 3.19% | 66.67K | $66.67K |
| 5 | CM Management, LLC | 1.32% | 27.50K | $27.50K |
| 6 | Morgan Stanley | 1.21% | 25.21K | $25.21K |
| 7 | Vanguard Capital Management LLC | 0.82% | 17.19K | $17.19K |
| 8 | Geode Capital Management, LLC | 0.70% | 14.65K | $14.65K |
| 9 | M28 Capital Management LP | 0.68% | 14.24K | $14.24K |
| 10 | FLPutnam Investment Management Company | 0.59% | 12.29K | $12.29K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CRIS
Curis Stock Price Forecast. Should You Buy CRIS? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE9ocmgxYUlHZ1lRNEFuM2dSb0xENEFpT3dvWTVtWFZGT09tc0V0ZjNBNkFERFJWZVVCdjZzNXA4ckV3NnFrVDRpMg?oc=5" target="_blank">Curis Stock Price Forecast. Should You Buy CRIS?</a> <font…
Curis (CRIS) Stock Faces Mixed Analyst Target Changes Over Execution And Pipeline Risk - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNendwZEhBaS00eHRBSlNINWZrVWlWVVRJU3VTdXhKeldkTG1OQS0yTDVYNno2VzNNZFNtM0poMVBCOHNPcVh2Zm1rUlE5cF9udkl4a2M1eGdzcnNUd2RUaGlsQm5zNHBaT0c4TkFjckpzUGk2X25DVGRuR3NpSnpreDNPSWNBX21xY1ZMTF…
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split - PR Newswire
<a href="https://news.google.com/rss/articles/CBMitgJBVV95cUxNY0tZTW93ckhFZE1iTFhKUnBIV0p4TWdpR2xtRG92YnJmSnUyOXJweFlKU1Y0V2dBQWhlTXJhZzIyRHhjYkZIWkQtaHBnMDFBVHlyalZkM3E3X2JXczRKOTdDM0JlNWdybXBRNkxNbzVZSmFnRHZKXzNMcnIxdmxmOUp4akJIWmgzNFBxVF…
Curis has consented 10 CLL patients; first five expected to dose by July's end - Stock Titan
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNV0Jmbk5HLVlMTmM3TlNPZHVmVG1XSU1UX2JjWDNITTd0ZXd0RmZjY1hzaWxDNmNCNW80UGEyOG5vUnI5c29OU0xZZ1RmM3hGbmU2Y1pOYkltLWd4bFhuZVotMkZSUEdhWktqRHdxUlFWRDVYOURuYS1BT091Xy1qY3ZNeVVFc3Y3Z0NNLU…
CRIS - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE85TE81Q1R5ZzUyRXJPTVFsdjFUYjNqVmxWMmxxdE5RVjBjVGEtRUNlbjEtMXBtclJnVWRhYzJyMEpSTzRNa1E?oc=5" target="_blank">CRIS</a> <font color="#6f6f6f">Finviz</font>…
Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQM2U1UVJfM21iLUhTVk1CMXhUVllmMmdrZWVoZEtMUDM2ckhmNk9HdVU1YWoyTDRXd0w1UzI4VjNzclQ0OWpYZTkxcUdXUWtvc2xPeXUzZlRYQXZZWmw5SU1kSTJRNkFDbDJSMjdLRzFJcVM5UVRJdjUxM083ajQtVllxQ1hvMDBsWWxHaC…
CRIS — Frequently Asked Questions
What is the current share price of Curis, Inc. (CRIS)?
As of 2026-09-19 21:16 PDT, Curis, Inc. (CRIS) trades at $1.27 on NasdaqCM. Its 52-week range is $1.27 to $36.60.
What is the market capitalisation of CRIS?
Curis, Inc. (CRIS) has a market capitalisation of $3.08M on NasdaqCM.
What is the P/E ratio of CRIS?
CRIS trades at a trailing price-to-earnings (P/E) ratio of 0.35. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.50.
Is CRIS a good stock to buy?
This page provides a data-driven analysis of Curis, Inc. (CRIS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.